Scholars@Duke

Therapy and clinical trials.

Publication ,  Journal Article
Sodhi, N; Krasuski, RA
Published in: Curr Opin Lipidol
June 2013
Published version (DOI) Open Access Copy (Duke) Link to item

Duke Scholars

Richard Andrew Krasuski
Author Richard Andrew Krasuski Medicine, Cardiology

Published In

Curr Opin Lipidol

DOI

10.1097/MOL.0b013e3283616351

EISSN

1473-6535

Publication Date

June 2013

Volume

24

Issue

3

Start / End Page

281 / 282

Location

England

Related Subject Headings

  • Serine Endopeptidases
  • Proprotein Convertases
  • Proprotein Convertase 9
  • Oligonucleotides
  • Niacin
  • Hyperlipoproteinemia Type II
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors
  • Humans
  • Drug Administration Schedule
  • Drug Administration Routes
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Sodhi, N., & Krasuski, R. A. (2013). Therapy and clinical trials. Curr Opin Lipidol, 24(3), 281–282. https://doi.org/10.1097/MOL.0b013e3283616351
Sodhi, Nishtha, and Richard A. Krasuski. “Therapy and clinical trials.” Curr Opin Lipidol 24, no. 3 (June 2013): 281–82. https://doi.org/10.1097/MOL.0b013e3283616351.
Sodhi N, Krasuski RA. Therapy and clinical trials. Curr Opin Lipidol. 2013 Jun;24(3):281–2.
Sodhi, Nishtha, and Richard A. Krasuski. “Therapy and clinical trials.” Curr Opin Lipidol, vol. 24, no. 3, June 2013, pp. 281–82. Pubmed, doi:10.1097/MOL.0b013e3283616351.
Sodhi N, Krasuski RA. Therapy and clinical trials. Curr Opin Lipidol. 2013 Jun;24(3):281–282.

Published In

Curr Opin Lipidol

DOI

10.1097/MOL.0b013e3283616351

EISSN

1473-6535

Publication Date

June 2013

Volume

24

Issue

3

Start / End Page

281 / 282

Location

England

Related Subject Headings

  • Serine Endopeptidases
  • Proprotein Convertases
  • Proprotein Convertase 9
  • Oligonucleotides
  • Niacin
  • Hyperlipoproteinemia Type II
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors
  • Humans
  • Drug Administration Schedule
  • Drug Administration Routes